mRNA Length Analysis Service
In the architecture of messenger RNA (mRNA) therapeutics, the precise length of the transcript is a foundational critical quality attribute (CQA). The presence of truncated species (shortmers) or unintended read-through products (longmers) can drastically alter the translational efficiency, stability, and safety profile of the drug substance. CD BioGlyco provides an industry-leading mRNA length analysis service that delivers high-resolution mapping of the entire molecular weight distribution of your RNA constructs. By utilizing advanced capillary electrophoresis and chromatographic techniques, we distinguish between full-length transcripts and nearly-identical impurities that standard analytical tools often fail to resolve. Our platform is designed to support the rigorous demands of vaccine development, gene editing, and protein replacement therapies.
To achieve the high fidelity required for therapeutic validation, CD BioGlyco employs a multi-platform approach that overcomes the inherent challenges of large, structured RNA molecules.
Utilizing optimized sieving matrices such as high-concentration polyvinylpyrrolidone (PVP), our CGE-LIF platform provides exceptional resolution for mRNA chain-length distribution, effectively separating full-length species from degraded fragments or incomplete transcripts.
This technique offers a high-resolution orthogonal method to assess mRNA length based on hydrophobicity and size, particularly useful for characterizing the purity of shorter and medium-length transcripts.
We provide absolute molecular weight determination, allowing for the characterization of mRNA in its native or denatured state without the need for reference standards.
For rapid screening, we utilize single-molecule imaging to measure the mass distribution of mRNA populations, identifying the presence of aggregates or significant length variations in a label-free environment.
Leveraging enzymatic cleavage (RNase T1) followed by liquid chromatography, we provide detailed insights into the length and heterogeneity of the poly(A) tail, which is critical for mRNA half-life.
Our service is designed to cover the entire lifecycle of mRNA development, from early discovery to late-stage quality control.
Upon arrival, each mRNA sample undergoes immediate stabilization in certified RNase-free buffers to prevent any degradation prior to analysis. We perform a dual verification of sample concentration and purity using fluorometric assays (e.g., Qubit) and spectrophotometry. This initial quality control ensures the starting material meets the stringent requirements for high-resolution length mapping, confirming that the sample is within the optimal detection range and free of contaminants that could interfere with subsequent analysis.
Therapeutic mRNA molecules frequently adopt complex secondary and tertiary structures that can mask their true length during electrophoresis. To overcome this, we apply a rigorous denaturation protocol involving precise thermal cycling in the presence of high-purity formamide and urea. This process effectively eliminates all intramolecular base pairing, ensuring each mRNA molecule is maintained in a linear, single-stranded conformation throughout the separation process, which is critical for accurate size determination.
Samples are analyzed using our premier capillary gel electrophoresis with CGE-LIF or IP-RP LC platforms. Each run is calibrated against a suite of RNA ladders and internal standards with precisely defined lengths. This calibration translates migration time or retention volume directly into nucleotide count, enabling exceptional resolution capable of distinguishing size variants differing by less than 100 nucleotides, even for transcripts exceeding 10 kb.
Following separation, our proprietary software algorithms perform advanced peak deconvolution and integration on the resulting electropherograms or chromatograms. This allows for the precise identification and quantification of the full-length mRNA peak relative to the "shortmer" (degradation/truncation) and "longmer" (incomplete transcription/aggregate) populations. We calculate critical parameters such as the polydispersity index (PDI) to quantify sample heterogeneity and map specific degradation patterns (e.g., 5'- vs. 3'-end bias).
The raw length distribution data is synthesized and interpreted within a broader biological context. Our reports go beyond simple percentages by integrating your integrity results with empirical "published data" on translational efficiency. This correlation provides a functional perspective on how the observed molecular weight distribution may impact protein yield and overall therapeutic performance, turning analytical data into actionable developmental insights.
Every project culminates in the delivery of a comprehensive analytical dossier and a consultative review session. The dossier includes all methodological details, raw data, calibrated electropherograms/chromatograms, and a summary of critical quality attributes. More importantly, our PhD-level specialists meet with your team to discuss the implications of the findings, offering expert guidance on optimizing IVT reactions, improving formulation stability, or addressing specific questions for pre-clinical and regulatory documentation.
Journal: Genome biology
DOI: 10.1186/s13059-018-1418-0
IF: 16.3
Published: 2018
Results: In this groundbreaking study, Anvar et al. employ full-length mRNA sequencing using PacBio's single-molecule long-read technology to comprehensively investigate the coordination between transcription initiation and mRNA processing events in the MCF-7 breast cancer cell line and human primary tissues. The research uncovers widespread interdependence between alternative transcription start sites (TSSs), splicing, and polyadenylation site (PAS) usage, revealing that these processes are tightly coupled on a single-molecule level, which significantly restricts the transcriptome's combinatorial complexity. By analyzing thousands of genes, the authors demonstrate that the choice of a TSS can influence splicing patterns and PAS selection, even over long genomic distances, challenging the notion of these as independent events. The study further validates key coupling events using Sanger sequencing and single-molecule RNA FISH, confirming the co-occurrence of specific features on individual mRNA molecules. Additionally, by integrating the full-length transcriptome data with shotgun proteomics, the authors predict and provide evidence for the translation of novel open reading frames, thereby linking transcriptional coordination to the proteomic landscape. This work fundamentally advances our understanding of gene regulation by demonstrating that transcription initiation and mRNA processing are functionally interconnected, providing a critical resource for future studies on transcriptome complexity and regulation.
Ex Vivo Cell Engineering
Monitoring the quality of mRNA used for the production of CAR-T cells, where the presence of shortmers can reduce transfection efficiency and the overall therapeutic window of the engineered cells.
Therapeutic Protein Production
Validating the consistency of mRNA constructs used in protein replacement therapies, where the maintenance of a specific poly(A) tail length distribution is vital for sustained therapeutic effect.
Rare Disease Drug Discovery
Supporting the development of orphan drugs by providing the high-resolution structural data required to optimize the IVT process for complex or non-standard mRNA sequences.
RNA Stability and Stress Testing
Assessing how various storage conditions and environmental stressors impact the molecular weight distribution of mRNA over time, aiding in the determination of optimal shelf-life.
Absolute Mass Determination
By integrating SEC with MALS technology, we provide the absolute molecular weight of your mRNA constructs, eliminating the inaccuracies associated with relative sizing against potentially mismatched RNA standards.
Rigorous Denaturation Protocols
Our specialized buffers and temperature-controlled separation environments prevent the re-annealing of complex secondary structures, ensuring that every peak in the electropherogram represents a true length variation rather than a conformational artifact.
High-Sensitivity Detection
Our LIF systems allow for the detection of trace-level shortmer impurities that are often invisible to UV-based detectors, providing a more conservative and safer assessment of product purity.
Customizable Analytical Matrices
We offer flexible separation parameters, adjusting voltage, temperature, and buffer concentration to provide the highest possible resolution for your specific mRNA length range, whether it is 1,000 or 12,000 nucleotides.
The resolution CD BioGlyco achieved with our 8kb saRNA was remarkable. They successfully identified a 5% shortmer contamination that our internal assays had completely missed.
— By Dr. J.P., Senior Scientist, Immunology Department
CD BioGlyco's length analysis has become a standard part of our batch-release protocol. Their data is consistently high-quality, and the reports are perfectly formatted for our regulatory filings.
— By Manager of Quality Control, Biopharma Group
Speed and accuracy are vital for our personalized vaccine program. CD BioGlyco delivered comprehensive length profiles for 20 different constructs in less than a week, allowing us to stay on schedule.
— By Dr. L. Chen, Director of R&D
Track the systemic and local distribution of your mRNA therapeutics post-administration to ensure target-specific delivery.
Evaluate the immune response to mRNA vaccines by measuring precise cytokine profiles in stimulated T cells.
Quantify the humoral immune response and the binding affinity of antibodies generated by mRNA-encoded antigens.
Assess the functional potency of the antibodies induced by your mRNA vaccine in neutralizing target pathogens.
CD BioGlyco is your strategic partner in ensuring the molecular integrity and therapeutic potential of mRNA products. Our mRNA length analysis service provides the critical data needed to navigate the complexities of RNA characterization with confidence. Whether you are optimizing a discovery-phase construct or validating a commercial manufacturing process, our team of experts is ready to support your journey from sequence to success, contact us!
Reference
